Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) Director David M. Mott bought 213,300 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were acquired at an average cost of $4.67 per share, with a total value of $996,111.00. Following the completion of the purchase, the director now owns 1,638,765 shares in the company, valued at $7,653,032.55. This represents a 14.96 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ardelyx Stock Down 5.0 %
Shares of Ardelyx stock traded down $0.24 on Monday, reaching $4.58. 3,569,324 shares of the company were exchanged, compared to its average volume of 4,888,104. The company has a current ratio of 4.03, a quick ratio of 3.87 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average of $5.45 and a 200 day moving average of $5.83. Ardelyx, Inc. has a one year low of $4.32 and a one year high of $10.13. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -15.27 and a beta of 0.83.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ARDX. Nisa Investment Advisors LLC lifted its stake in shares of Ardelyx by 1,026.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 3,233 shares during the last quarter. Redwood Wealth Management Group LLC bought a new stake in shares of Ardelyx during the 2nd quarter valued at $62,000. Coastal Bridge Advisors LLC acquired a new stake in shares of Ardelyx during the 2nd quarter worth $74,000. Helen Stephens Group LLC bought a new position in shares of Ardelyx in the third quarter worth $76,000. Finally, CWM LLC raised its stake in Ardelyx by 328.1% in the third quarter. CWM LLC now owns 12,814 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 9,821 shares in the last quarter. 58.92% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
View Our Latest Report on ARDX
About Ardelyx
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Featured Articles
- Five stocks we like better than Ardelyx
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- What Investors Need to Know to Beat the Market
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What is the Euro STOXX 50 Index?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.